Welcome to Jianke online pharmacy! Sign in Free registration

Hydroxychloroquine sulfate tablets (saineng)

Common name:
Hydroxychloroquine sulfate tablets
Product No.:
B14202213797
Approval No.:
H20160306 (h20140128) (imported with original packaging)
Main functions:
For the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, juvenile chronic arthritis, skin lesions caused or exacerbated by sunlight.
Product specification:
0.2g*10s
Manufacturer:
Sanofi-Synthelabo Ltd.
This product is off the shelf!

Recommendation of similar products

  • Product introduction
  • instructions
  • Qualification certificate
  • User evaluation(1057)
  • Related questions and answers
  • Relevant information
Product name Hydroxychloroquine sulfate tablets (saineng)
Main raw materials The main component of this product is hydroxychloroquine sulfate.
Main role For the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, juvenile chronic arthritis, skin lesions caused or exacerbated by sunlight.
Suitable population
Product specification 0.2g*10s
Usage and dosage [usage and dosage] Tablets are given orally Adults (including the elderly) The first dose for adults is 400mg per day. When the efficacy is no longer further improved, the dose can be reduced to 200mg for maintenance. If the treatment response is weakened, the maintenance dose should be increased to 400mg per day. The minimum effective dose should not exceed 65mg / kg / day (calculated from the ideal body weight rather than the actual body weight) or 400mg / day, or even less. children The minimum effective dose should be no more than 65 mg / kg / day (based on ideal body weight) or 400 mg / day, or even less. It is forbidden for children younger than 6 years old, and 200mg tablet is not suitable for children weighing less than 35 / kg. Every time you take medicine, you should eat or drink milk at the same time. Hydroxychloroquine has a cumulative effect, and it takes several weeks to play its beneficial role. Slight adverse reactions may occur relatively early. If rheumatic diseases do not improve after 6 months of treatment, the treatment should be terminated. In the case of light sensitive diseases, treatment should be given only to the greatest extent of exposure to sunlight.
manufacturing enterprise Sanofi-Synthelabo Ltd.
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for all purchased goods.

  • Private packaging, privacy protection

    When Jianke is packing and delivering goods, the appearance of the packing box only shows the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of Jianke are delivered by the third-party logistics to the nearest warehouse according to your delivery address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure the quality of drugs. Specially assigned person to manage and ensure product inventory.

[drug name] Hydroxychloroquine sulfate tablets (saineng)

[common name] Hydroxychloroquine sulfate tablets

[specification and model] 0.2g*10s

[manufacturer] Sanofi-Synthelabo Ltd.

[drug type] Western medicine

[approval No.] H20160306 (h20140128) (imported with original packaging)

[validity period] 24 months

[functional indications] For the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, juvenile chronic arthritis, skin lesions caused or exacerbated by sunlight.

[usage and dosage] [usage and dosage] Tablets are given orally Adults (including the elderly) The first dose for adults is 400mg per day. When the efficacy is no longer further improved, the dose can be reduced to 200mg for maintenance. If the treatment response is weakened, the maintenance dose should be increased to 400mg per day. The minimum effective dose should not exceed 65mg / kg / day (calculated from the ideal body weight rather than the actual body weight) or 400mg / day, or even less. children The minimum effective dose should be no more than 65 mg / kg / day (based on ideal body weight) or 400 mg / day, or even less. It is forbidden for children younger than 6 years old, and 200mg tablet is not suitable for children weighing less than 35 / kg. Every time you take medicine, you should eat or drink milk at the same time. Hydroxychloroquine has a cumulative effect, and it takes several weeks to play its beneficial role. Slight adverse reactions may occur relatively early. If rheumatic diseases do not improve after 6 months of treatment, the treatment should be terminated. In the case of light sensitive diseases, treatment should be given only to the greatest extent of exposure to sunlight.

[adverse reactions] Visual images: retinal changes and corneal changes, skin effects, gastrointestinal effects, central nervous system effects, muscle nerve effects, cardiovascular system effects, hematological effects, liver effects, allergic reactions, metabolic and nutritional system effects. (see the inner packaging manual for details)

[precautions] Before starting long-term treatment with this product, all patients should undergo ophthalmic examination. The examination includes visual acuity, central visual field, color vision box, fundus examination, etc. Thereafter, it shall be inspected at least once a year. There is a great correlation between retinal diseases and drug doses. When the maximum daily dose does not exceed 6.5mg/kg body weight, the risk of retinal damage is low. However, exceeding the recommended daily dose will greatly increase the risk of retinal toxicity. (see the inner packaging instructions for details) please read the instructions carefully and follow the doctor's instructions.

[taboo] 1. Patients with pre-existing spectacle macular disease; 2. It is forbidden for patients known to be allergic to 4-aminoquinoline compounds; Children under 3.6 years old (200mg tablet is not suitable for children weighing less than 35kg)

[listing Permit Holder] Sanofi-SynthelaboLtd.

[packaging unit] box

[main ingredients] The main component of this product is hydroxychloroquine sulfate.

[character] The white film coated tablets show white after removing the coating, with HCQ engraved on one side and 200 engraved on the other side.

[medication for pregnant and lactating women] Hydroxychloroquine can pass through the placenta. There is limited information on the use of hydroxychloroquine during pregnancy. It should be noted that therapeutic doses of 4-chloroquinoline are associated with central nervous system damage, including ototoxicity (auditory and vestibular toxicity, congenital deafness), retinal hemorrhage and retinal pigmentation. Therefore, hydroxychloroquine should be avoided in pregnant women unless the potential therapeutic benefits outweigh the potential risks according to the doctor's assessment. Lactating women should use hydroxychloroquine with caution, because a small amount of hydroxychloroquine can be secreted in breast milk, and infants are known to be very sensitive to the toxic effects of 4-aminoquinoline.

[medication for children] The minimum limited dose should be used and should not exceed 6.5mg/kg/day (based on ideal body weight) or 400mg / day, or even less. It is forbidden for children younger than 6 years old, and 200mg tablet is not suitable for children weighing less than 35kg.

[medication for elderly patients] Not yet clear.

[storage] seal up.

Praise degree

zero%

    Activity topics